Study of humoral and cellular immunity in vaccinated with mRNA-1273
MetadataShow full item record
AuthorGutiérrez Bautista, Juan Francisco; López Nevot, Miguel Ángel; Gómez Vicente, Esther; Quesada, Trinidad; Marín, Eva María; Rodríguez, Ana; Rodríguez, Ana Isabel; Rodríguez Granger, Javier; Cobo, Fernando; Sampedro, Antonio
John Wiley & Sons
Moderna vaccineHumoral responseSARS-CoV-2mRNA vaccinesmRNA-1273 vaccine
Gutiérrez-Bautista, JF... [et al.]. Study of humoral and cellular immunity in vaccinated with mRNA-1273. APMIS. 2022; 00: 1– 9. DOI [10.1111/apm.13215]
SponsorshipInvestigacion y Desarrollo (I + D) del Sistema Andaluz de Salud (SAS); Instituto de Salud Carlos III European Commission FIS PI21/01708
The new vaccines against SARS-CoV-2 have raised a lot of expectations about their ability to induce immunity and the duration of this. This is the case of mRNA vaccines such as Moderna’s mRNA-1273. Therefore, it is necessary to study the humoral and cellular immunity generated by these vaccines. Our objectives are determining what is the normal response of antibody production, and what is the level of protective antibodies and monitoring patients in case of subsequent infection with COVID-19. We present the first results of a longitudinal study of the humoral response in 601 health workers vaccinated with Moderna. The results show a humoral immunity at 90 days after the second dose of 100%, with a strong decrease between the levels of circulating anti-S IgG antibodies between days 30 and 90 postvaccination. Observing a steeper decline in those who had higher titles at the beginning. In addition, we present a cellular response of 86% at three months after the second dose, which is related to low humoral response.